Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study
- PMID: 25001493
- PMCID: PMC4107480
- DOI: 10.1186/1472-6823-14-54
Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study
Abstract
Background: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare neuroendocrine tumors, and lack of data in Asian populations especially in China. The aim of this retrospective study was to assess the clinical, pathological and prognostic characteristics of GEP-NENs in China.
Methods: We collected clinical and pathological data of 168 patients diagnosed with GEP-NENs and treated at the First and Second Affiliated Hospitals of Dalian Medical University between January 2003 and December 2012. Kaplan-Meier method and log rank analysis was used to analyze the prognostic significance of clinical and pathological characteristics.
Results: Mean age was 51.83 ± 14.03 and the male-to-female ratio was 1.5:1. Primary sites were the rectum (58.93%), pancreas (13.69%), stomach (9.52%), duodenum (5.36%), colon (4.76%), appendix (4.76%), ileum (2.38%) and jejunum (0.60%). Most patients (95.83%) presented non-functional tumors with non-specific symptoms such as abdominal or back pain (29.17%) and gastrointestinal bleeding (25.60%). Based on the 2010 World Health Organization (WHO) classification, patients were diagnosed with neuroendocrine tumor (NET) (24.40%) or neuroendocrine carcinoma (NEC) (7.14%). The estimated mean survival was 8.94 ± 0.28 years (95% CI: 8.40-9.48). Male gender, young age, small tumor size and NET tumor type were favorable prognostic factors.
Conclusion: Chinese GEP-NENs patients present characteristics that are similar to American and European patients. However, there is an urgent need to establish a national database for understanding the clinical and epidemiological features of GEP-NENs in China.
Figures
Similar articles
-
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Mil Med Res. 2024 Jun 4;11(1):35. doi: 10.1186/s40779-024-00535-6. Mil Med Res. 2024. PMID: 38835066 Free PMC article. Review.
-
Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.BMC Endocr Disord. 2017 Jul 13;17(1):39. doi: 10.1186/s12902-017-0190-6. BMC Endocr Disord. 2017. PMID: 28705205 Free PMC article. Clinical Trial.
-
Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.Chin J Cancer. 2017 Jun 21;36(1):51. doi: 10.1186/s40880-017-0218-3. Chin J Cancer. 2017. PMID: 28637502 Free PMC article.
-
Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.Pol Arch Med Wewn. 2015;125(5):337-46. doi: 10.20452/pamw.2832. Epub 2015 Apr 29. Pol Arch Med Wewn. 2015. PMID: 25924181
-
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.Front Endocrinol (Lausanne). 2024 Sep 30;15:1424839. doi: 10.3389/fendo.2024.1424839. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39411312 Free PMC article. Review.
Cited by
-
Underwater endoscopic mucosal resection for rectal neuroendocrine tumors (with videos): a single center retrospective study.BMC Gastroenterol. 2022 Jun 2;22(1):276. doi: 10.1186/s12876-022-02350-6. BMC Gastroenterol. 2022. PMID: 35655173 Free PMC article.
-
Development and validation of predictive models for distant metastasis and prognosis of gastroenteropancreatic neuroendocrine neoplasms.Sci Rep. 2025 Mar 19;15(1):9510. doi: 10.1038/s41598-025-92974-x. Sci Rep. 2025. PMID: 40108260 Free PMC article.
-
Impact of Sex and Deprivation on Neuroendocrine Tumour Survival: Challenges of Heterogeneous Data.Neuroendocrinology. 2025 Apr 29:1-24. doi: 10.1159/000546128. Online ahead of print. Neuroendocrinology. 2025. PMID: 40300589 Free PMC article. Review.
-
Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.Biomed Res Int. 2018 Mar 27;2018:1013640. doi: 10.1155/2018/1013640. eCollection 2018. Biomed Res Int. 2018. PMID: 29780816 Free PMC article.
-
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Mil Med Res. 2024 Jun 4;11(1):35. doi: 10.1186/s40779-024-00535-6. Mil Med Res. 2024. PMID: 38835066 Free PMC article. Review.
References
-
- Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72. - PubMed
-
- Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. - PubMed
-
- Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18. vii. - PubMed
-
- Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92(8):2204–2210. - PubMed
-
- Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113(10):2655–2664. - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical